XNASIPSC
Market cap77mUSD
Jan 17, Last price
0.91USD
1D
0.45%
1Q
-43.17%
IPO
-96.38%
Name
Century Therapeutics Inc
Chart & Performance
P/E
—
P/S
34.59
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2m
-57.01%
Net income
-137m
L+4.38%
CFO
-88m
L
Profile
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 2,235 -57.01% | 5,199 | |||
Cost of revenue | 140,460 | 149,101 | |||
Unusual Expense (Income) | |||||
NOPBT | (138,225) | (143,902) | |||
NOPBT Margin | |||||
Operating Taxes | 1,881 | 91 | |||
Tax Rate | |||||
NOPAT | (140,106) | (143,993) | |||
Net income | (136,673) 4.38% | (130,932) 36.64% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 516 | 27,158 | |||
BB yield | -0.26% | -9.17% | |||
| Debt | |||||
Debt current | 1,513 | 6,977 | |||
Long-term debt | 93,316 | 81,610 | |||
Deferred revenue | 111,381 | 110,834 | |||
Other long-term liabilities | 56 | 718 | |||
Net debt | (167,005) | (278,765) | |||
| Cash flow | |||||
Cash from operating activities | (88,348) | 14,052 | |||
CAPEX | (13,736) | (30,604) | |||
Cash from investing activities | 61,132 | (13,128) | |||
Cash from financing activities | (9,725) | 27,158 | |||
FCF | (120,457) | (185,902) | |||
| Balance | |||||
Cash | 172,738 | 315,498 | |||
Long term investments | 89,096 | 51,854 | |||
Excess cash | 261,722 | 367,092 | |||
Stockholders' equity | (655,657) | (521,554) | |||
Invested Capital | 1,000,015 | 985,258 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 59,314 | 57,756 | |||
Price | 3.32 -35.28% | 5.13 -67.65% | |||
Market cap | 196,924 -33.54% | 296,287 -66.04% | |||
EV | 29,919 | 17,522 | |||
EBITDA | (125,181) | (135,462) | |||
EV/EBITDA | |||||
Interest | 540 | 1,105 | |||
Interest/NOPBT | |||||